Gast ::
| Hauptseite > Publikationsdatenbank > The D-amino acid peptide D3 reduces amyloid fibril boosted HIV-1 infectivity > print |
| Hauptseite > Publikationsdatenbank > The D-amino acid peptide D3 reduces amyloid fibril boosted HIV-1 infectivity > print |
| 001 | 151101 | ||
| 005 | 20210129213413.0 | ||
| 024 | 7 | _ | |a 10.1186/1742-6405-11-1 |2 doi |
| 024 | 7 | _ | |a WOS:000332026100001 |2 WOS |
| 024 | 7 | _ | |a 2128/5907 |2 Handle |
| 024 | 7 | _ | |a altmetric:2043536 |2 altmetric |
| 024 | 7 | _ | |a pmid:24422713 |2 pmid |
| 037 | _ | _ | |a FZJ-2014-01123 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Widera, Marek |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a The D-amino acid peptide D3 reduces amyloid fibril boosted HIV-1 infectivity |
| 260 | _ | _ | |a London |c 2014 |b BioMed Central |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1410176927_24690 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a article |2 DRIVER |
| 520 | _ | _ | |a BackgroundAmyloid fibrils such as Semen-Derived Enhancer of Viral Infection (SEVI) or amyloid-β-peptide (Aβ) enhance HIV-1 attachment and entry. Inhibitors destroying or converting those fibrils into non-amyloidogenic aggregates effectively reduce viral infectivity. Thus, they seem to be suitable as therapeutic drugs expanding the current HIV-intervening repertoire of antiretroviral compounds.FindingsIn this study, we demonstrate that the small D-amino acid peptide D3, which was investigated for therapeutic studies on Alzheimer’s disease (AD), significantly reduces both SEVI and Aβ fibril boosted infectivity of HIV-1.ConclusionsSince amyloids could play an important role in the progression of AIDS dementia complex (ADC), the treatment of HIV-1 infected individuals with D3, that inhibits Aβ fibril formation and converts preformed Aβ fibrils into non-amyloidogenic and non-fibrillar aggregates, may reduce the vulnerability of the central nervous system of HIV patients for HIV associated neurological disorders.Keywords:HIV-1 infection; SEVI; D3; Amyloid-beta; Alzheimer’s disease; D-enantiomeric peptide; Drugs; Monomers; Oligomers |
| 536 | _ | _ | |a 452 - Structural Biology (POF2-452) |0 G:(DE-HGF)POF2-452 |c POF2-452 |f POF II |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, juser.fz-juelich.de |
| 700 | 1 | _ | |a Klein, Antonia Nicole |0 P:(DE-Juel1)145785 |b 1 |
| 700 | 1 | _ | |a Cinar, Yeliz |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Funke, Susanne |0 P:(DE-HGF)0 |b 3 |e Corresponding author |
| 700 | 1 | _ | |a Willbold, Dieter |0 P:(DE-Juel1)132029 |b 4 |
| 700 | 1 | _ | |a Schaal, Heiner |0 P:(DE-HGF)0 |b 5 |e Corresponding Author |
| 773 | _ | _ | |a 10.1186/1742-6405-11-1 |g Vol. 11, no. 1, p. 1 - |0 PERI:(DE-600)2173450-1 |n 1 |p 1 - 7 |t AIDS research and therapy |v 11 |y 2014 |x 1742-6405 |
| 856 | 4 | _ | |u http://www.aidsrestherapy.com/content/11/1/1 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/151101/files/FZJ-2014-01123.pdf |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:151101 |p openaire |p open_access |p driver |p VDB |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)145785 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)132029 |
| 913 | 2 | _ | |a DE-HGF |b Key Technologies |l BioSoft Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences |1 G:(DE-HGF)POF3-550 |0 G:(DE-HGF)POF3-553 |2 G:(DE-HGF)POF3-500 |v Physical Basis of Diseases |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Schlüsseltechnologien |1 G:(DE-HGF)POF2-450 |0 G:(DE-HGF)POF2-452 |2 G:(DE-HGF)POF2-400 |v Structural Biology |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF2 |l BioSoft |
| 914 | 1 | _ | |y 2014 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 2.0 |0 LIC:(DE-HGF)CCBY3 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a Peer review unknown |0 StatID:(DE-HGF)0040 |2 StatID |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)ICS-6-20110106 |k ICS-6 |l Strukturbiochemie |x 0 |
| 980 | 1 | _ | |a FullTexts |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a FullTexts |
| 981 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|